BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success

BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue to $502.1 million. This was driven largely by the commercial success of its flagship product, Attruby. In Q4 alone, Attruby generated $146 million in net product revenue, reflecting a 35% increase over Q3. This growth was supported by 7,804 new patient starts and high levels of patient persistence. The compa ...